LPM 6690176
Alternative Names: LPM-6690176; LY-01024Latest Information Update: 31 Mar 2024
Price :
$50 *
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 12 Mar 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (PO) (NCT06240546)
- 05 Feb 2024 Luye Pharma Group plans phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Unresectable/Inoperable) in February 2024 (PO, Capsule) (NCT06240546)
- 05 Feb 2024 Preclinical trials in Solid tumours in China (PO) before February 2024 (NCT06240546)